Human beings, like all other animals with a backbone, have an internal regulation
system that helps the body stay sound. This endocannabinoid system, or ECS
for short, keeps our biochemistry in balance and stimulates pleasure—in
essence, it contributes to leading a healthy, happy life (Moskowitz, 2017: 24).
Although it was only discovered as recently as the 1990s (De Petrocellis, Cascio
& Di Marzo 2004), the ECS plays a major role in functions involving our central
nervous system and peripheral nervous system (Pacher, Bátkai & Kunos, 2006),
the latter of which relays information from our brain and spine to the rest of the
Thanks to continued research, we now know that the ECS comprises three
- the cannabinoid receptors, called CB1 and CB2
- the molecules that activate these receptors and lend their name to
the system, endocannabinoids
- metabolic enzymes, which produce and break down the
endocannabinoids (Nagarkatti, Pandey, Rieder, Hegde &
The ECS and cannabis are often mentioned in the same breath because their
study is historically tied. In fact, researching cannabis led to the detection of the
ECS. For millennia, people have been consuming Cannabis sativa as medicine
and for recreation, but only three decades ago, when exploring the effects of
cannabis’s psychoactive component, did a team of scientists find that vertebrates
have specific receptors responding to the plant’s chemical compounds (De
Petrocellis, Cascio & Di Marzo, 2004). The most commonly cited compounds are
the psychoactive component (-)-Δ 9 -tetrahydrocannabinol (THC) and the non-
psychoactive component cannabidiol (CBD).
An understanding of the ECS works like a master key, providing the power to
unlock cannabis’s therapeutic promise (Di Marzo, Bifulco & De Petrocellis, 2004;
Ligresti, Petrosino & Di Marzo, 2009) for a broad spectrum of health issues.
- Alzheimer’s disease
- Gastrointestinal disorders
- Neurodegenerative disorders
- Neurological disorders
- Pain & inflammation
- Post-traumatic stress disorders
- Ribavirin-induced anorexia
- Weight loss
The list goes on. Further research and knowledge are still needed. In the
meantime, Tikva is backed by science that is blazing a trail to uncover more
about the ECS, its impact on various bodily functions, and its receptiveness to
De Petrocellis, L., Cascio, M.G., & Di Marzo, V. (2004). The endocannabinoid
system: A general view and latest additions. British Journal of Pharmacology.
141(5), 765-774. doi.org/10.1038/sj.bjp.0705666
Di Marzo, V., Bifulco, M., & De Petrocellis, L. (2004). The endocannabinoid
system and its therapeutic exploitation. Nature Reviews, 3, 771-784.
Ligresti, A., Petrosino, S., & Di Marzo, V. (2009). From endocannabinoid profiling
to ‘endocannabinoid therapeutics.’ Current Opinion in Chemical Biology, 13, 321-
Moskowitz, M. (2017). Medical cannabis: A guide for patients, practitioners, and
caregivers. Virginia Beach: Köehler Books.
Nagarkatti, P., Pandey. R, Rieder, S., Hegde, V., & Nagarkatti, M. (2009).
Cannabinoids as novel anti-inflammatory drugs. Future Medicinal Chemistry,
1(7), 1333-1349. doi.org/10.4155/fmc.09.93
Pacher, P., Bátkai, S. & Kunos, G. (2006). The endocannabinoid system as an
emerging target of pharmacotherapy. Pharmacological Reviews, 58(3), 389-462.